New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:42 EDTCVMFrance clears CEL-SCI for patient enrollment in Phase III trial
CEL-SCI announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey. CEL-SCI’s Phase III trial is assessing the company’s investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
09:43 EDTCVMCEL-SCI to raise $1M in registered direct offering
Subscribe for More Information
09:22 EDTCVMCEL-SCI prices public offering of stock, warrants at 76c
CEL-SCI announced that it has priced a “best efforts” underwritten public offering of common stock and warrants at a combined price of 76c for aggregate gross proceeds of $6M. For every four shares sold, the company will issue to investors in the offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24. CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, other research and development, and general and administrative expenses. Laidlaw & Company is acting as the sole book-running manager and underwriter for the proposed offering.
09:15 EDTCVMOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Apple (AAPL), up 3%... Texas Instruments (TXN), up 2.3%... Harley Davidson (HOG), up 7%... Celanese (CE), up 4%... United Technologies (UTX), up 1.4%. ALSO HIGHER: Neonode (NEON), up 20% after signing technology development agreement with global tier-one printer OEM... Illumina (ILMN), up 10%, upgraded at Janney Capital following the company's better than expected Q3 earnings. DOWN AFTER EARNINGS: Coca-Cola (KO), down 5%... Chipotle (CMG), down 4.6%... Verizon (VZ), down 1%. ALSO LOWER: CEL-SCI (CVM), down 15.3% after announcing proposed offering of common stock, warrants... Omeros (OMER), down 12% after suspending Huntington's clinical trial with OMS824... Tesoro Logistics (TLLP), down 2.4% after 20M share secondary priced at $57.47... Rhino Resources (RNO), down 53%, downgraded to Underperform at Raymond James following the reduction in its quarterly cash dividend.
October 20, 2014
18:51 EDTCVMOn The Fly: After Hours Movers
Subscribe for More Information
16:57 EDTCVMCEL-SCI down 17.7% after announcing proposed offering of common stock, warrants
16:31 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use